Recent Finacing
Recent Raise
NeuroGenetic Pharmaceuticals develops NGP 555, a proprietary small-molecule therapy for Alzheimer’s disease, and conducts preclinical research and clinical trial development from its San Diego operations.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors